sorry, we can't preview this file
...but you can still download Supplementary Material.docx
Supplementary Material.docx (979.73 kB)
FMB-2021-0215 Supplementary Material
figure
posted on 2022-03-23, 09:00 authored by Camila Maríngolo Ribeiro, Júlia A. Grecco, Débora L. Bellato, Aryadne Larissa de Almeida, Vanessa Pietrowski Baldin, Katiany Rizzieri Caleffi-Ferracioli, Fernando Rogério PavanSupplementary figure 1. Relative fluorescence due to the accumulation of ethidium bromide in the clinical isolate of Mycobacterium tuberculosis CF 110 after different pretreatments and in the presence of efflux pump inhibitors.
CCCP = m-chlorophenyl hydrazine; VP = verapamil; RES = reserpine; OFL = ofloxacin. The results are the mean of two independent assays.
Supplementary figure 2. Relative fluorescence due to the accumulation of ethidium bromide in the clinical isolate of Mycobacterium tuberculosis CF 169 after different pretreatments and in the presence of efflux pump inhibitors.
CCCP = m-chlorophenyl hydrazine; VP = verapamil; RES = reserpine; OFL = ofloxacin;
STP = streptomycin. The results are the mean of two independent assays.
Supplementary figure 3. Relative fluorescence due to the accumulation of ethidium bromide in the laboratorial strains of Mycobacterium tuberculosis H37Rv after different pretreatments and in the presence of efflux pump inhibitors.
CCCP = m-chlorophenyl hydrazine; VP = verapamil; RES = reserpine; OFL = ofloxacin;
STP = streptomycin. The results are the mean of two independent assays.
